Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629497 · ClinicalTrials.gov registry record · Early Phase 1
Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus
A Early Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT02629497 is a Early Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 90 participants.
The verdict
NCT02629497, a Early Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.
Interventions
- DIETARY_SUPPLEMENT Fish Oil
- DIETARY_SUPPLEMENT Primrose oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02629497
The ClinicalTrials.gov registry entry for NCT02629497 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fish Oil is the first listed.
NCT02629497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02629497 about?
NCT02629497 is a clinical study titled "Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus". This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post...
What is the current status of trial NCT02629497?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2015-11. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02629497?
The interventions under investigation include: Fish Oil (DIETARY_SUPPLEMENT), Primrose oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02629497?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.